Introduction
Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related death globally and its incidence continues to rise [
1]. Currently, treatment options for advanced HCC patients are quite limited, resulting in an extremely low 5-year survival rate. HCC is associated with hepatitis B virus, hepatitis C virus, alcohol, aflatoxin and nitrosamines. However, the underlying molecular mechanisms involved in tumor formation and pathogenesis are unclear. Therefore, it is imperative to identify new molecular targets for the diagnosis and therapy of HCC.
Cytochrome P450 (CYP) enzymes are a superfamily of hemoproteins and extensively catalyze the metabolism of exogenous and endogenous compounds. CYP also exerts a crucial role in the development and progression of cancer, diabetes, heart disease, and Parkinson's disease [
2‐
5]. CYP2E1 is the most abundant CYP isoform in human liver and is the main enzyme that metabolizes a number of low molecular weight compounds, such as ethanol, acetaminophen, benzene, and carbon tetrachloride, and cancer suspects like nitrosamines and azo compounds [
6,
7]. Owing to its contribution to the metabolic activation of procarcinogens, many studies have explored the relevance of CYP2E1 to HCC susceptibility. For example, CYP2E1 catalyzes alcohol oxidation to acetaldehyde under long-term consumption of ethanol, and acetaldehyde forms DNA adducts, which may play an important role in hepatocarcinogenesis in patients with alcoholic liver injury [
8]. In addition, CYP2E1 converts diethylnitrosamine to genotoxic products which damage DNA irreversibly, leading to hepatocarcinogenesis in rat studies.
However, the most common etiology of HCC is viral infection (hepatitis B virus and hepatitis C virus), not procarcinogens. Especially in China, 85% of HCC cases are associated with chronic HBV infection [
9,
10]. Our knowledge of CYP2E1 in non-procarcinogen-related HCC is limited. Recently, several groups independently revealed that both the expression level and the activity of CYP2E1 are decreased in HCC as compared to adjacent normal liver tissues [
11,
12]. From liver lesion and cirrhosis to the tumor occurrence, in the rat HCC model of hepatocarcinogenesis the expression level of CYP2E1 gradually decreased with the aggravation of liver lesion [
13]. As the downregulation of CYP2E1 occurred earlier than the onset of tumor occurrence, it was possible that decreased CYP2E1 might play a role in hepatocarcinogenesis. Indeed, decreased CYP2E1 was associated with poorly differentiated HCC and poor prognosis of patients with HCC [
14]. These findings imply that high expression of CYP2E1 might have an inhibitory role in HCC development. In fact, elevated CYP2E1 level by alcohol induction [
15], ectopic expression [
16,
17], or exposure to TSA [
18] is cytotoxic to HCC cells and inhibits their rapid proliferation. Thus, CYP2E1 may play multiple roles at different stages during hepatocarcinogenesis, which merits more detailed investigation.
CYP2E1 has been shown to be involved in many signaling pathways, such as the AKT [
19], PPARα[
20], EGFR/c-Raf, ERK1/2 [
21], MAPK [
22], Nrf2/HO-1, NF-κB [
23], and the JNK pathways [
24]. Wnt/β-catenin signaling is frequently deregulated in HCC, where activation of Wnt leads to HCC initiation, progression, invasion, and metastasis [
25]. Up to 70% of HCCs exhibit increased Wnt/β-catenin signaling, and
CTNNB1 (β-catenin) mutations are elevated with HCC progression [
26]. However, the relationship between CYP2E1 and Wnt/β-catenin signaling is unknown.
The current study was designed to unravel the roles of CYP2E1 in the pathogenesis of HCC. We investigated: (1) whether CYP2E1 has a protective role in the malignant biological behavior of HCC; (2) if so, whether CYP2E1 acts as a tumor suppressor by regulating the Wnt/β-catenin pathway in HCC, and (3) the potential links between CYP2E1 suppression and the Wnt/β-catenin pathway in HCC.
Materials and methods
Patients and tissue samples
A total of 88 HCC and adjacent non-tumor tissues were collected from patients who underwent liver cancer hepatectomy at the Affiliated Cancer Hospital of Zhengzhou University (Zhengzhou, China) from July 2016 to December 2017, of which 81 samples were paired. Detailed information of the sample refers to Additional file
1: Table S1. The ethics committee of Zhengzhou University approved the protocol (18 March 2016; Approved No: 2016-0177) and all the patients gave written informed consent. In addition, all specimens were subjected to RT-qPCR after RNA extraction, and 36 and 20 samples were used for western blot and immunohistochemical verification, respectively.
Cell culture and reagents
Human liver cell lines SMMC-7721, HepG2, MHCC-97H, Huh7, Bel-7402 were donated by Dr. Tingting Liu (Sino-American Hormelian Cancer Research, Zhengzhou, P.R. China) and Prof. Ping Xu (State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences, Beijing, P.R. China). HCC-LM3 was purchased from China Center for Type Culture Collection (Wuhan, China). All cell lines were cultured at 37 °C with 5% CO2 and grown in Dulbecco's modified Eagle's medium (BI, Shanghai) supplemented with 10% fetal bovine serum, 100 U/ml penicillin and 100 μg/ml streptomycin. 3-Methyladenine (3-MA) was provided by Santa Cruz Biotechnology (sc-205596). N-Acetyl-l-cysteine (NAC) and the CYP2E1 inhibitor clomethiazole (CMZ) was purchased from Yuanye Bio-Technology (Shanghai, China).
RT-qPCR
RT-qPCR was performed according to our previous study [
6] and the primers used are listed in Additional file
1: Table S2. Briefly, total RNA was extracted by the RNAiso Plus kit (Takara Bio Inc.). The PrimeScript RT reagent kit (Takara Bio Inc) was used to synthesize the cDNA from 1 μg of total RNA. The transcript levels of the target genes were measured by an ABI 7500 Fast Real-Time PCR system.
GAPDH was used as a reference gene.
Western blot
Western blot assays were performed as described recently [
27]. Briefly, cells were lysed on ice and proteins were fractionated by SDS-PAGE. Then the protein was transferred onto a PVDF membrane, which was incubated with the indicated antibody and ECL solution. The signal was visualized with an ECL detection system. Antibodies used include anti-CYP2E1 (ab28146, from Abcam, UK); anti-c-Myc (10828-I-AP), Goat anti-rabbit IgG (HL) (SA00001-2), anti-β-Catenin (66379-1-Ig), goat anti-mouse IgG (HL) (SA00001-1), anti-LEF1 (14972-1-AP) (from Proteintech, Wuhan, China); anti-GAPDH (6C5, sc-47724), anti-β-actin (C4, sc-47778), anti-Dvl2 (D-11, sc-390303), anti-TCF-4 (D-4, sc-166699), anti-KLHL12 (D-1, sc-514874), anti-Ub antibody (P4D1, sc-8017) (from Santa Cruz Biotechnology, Inc, USA); anti-E-cadherin (WL01482), anti-Twist (WL00997), anti-N-cadherin (WL01047), anti-Snail (WL01863), anti-Vimentin (WL01960), and anti-Slug (WL01508) from Wanlei Life Sciences, Shenyang, China.
Gene expression manipulations
Vector lentivirus and lentivirus encoding human CYP2E1 (EX-I0304-Lv201 and EX-NEG-Lv201) were provided by GeneCopoeia (Guangzhou, China). Control or CYP2E1 vectors were first mixed with packaging plasmids (Lenti-Pac™ HIV, GeneCopoeia company) and then were co-transfected into HEK293T cells by Lipofectamine 2000 (Thermo Fisher Scientific Inc). Culture supernatants were collected and purified (LPR-LCS-01, GeneCopoeia, Guangzhou, China) at 48 h after transfection. In the presence of 8 μg/ml polybrene, MHCC-97H and SMMC-7721 cells were infected with the virus particles and finally, puromycin was used to select the infected cells. The overexpression of CYP2E1 in transfected cells was verified by RT-qPCR and western blot. To overexpress Dvl2, the full-length Dvl2 plasmid (GV417-Dvl2) was transiently infected into the CYP2E1 stable cells by VigoFect (Vigorous Biotechnology).
Cell migration assay
For cell migration assay, HCC cells were plated in 6-well plates and grown to confluence. The cell monolayer was scratched with a sterile 10 μl pipette tip and exchanged with serum-free DMEM after washing twice with PBS. The images of the wounds were recorded at the same position using an inverted microscope (Nikon ECLIPSE TS100, Japan) at 0 h, 24 h, 48 h and 72 h, respectively. The width between wounds was detected by Image J software (National Institutes of Health).
Cell invasion assay
For cell invasion capacity, the Transwell chamber was coated with 100 μl 1: 8 diluted Matrigel (BD BioCoat, Corning, USA) and incubated for 5 h. Next, 5 × 104 cells in serum-free medium (200 μl) was seeded at the upper chamber, and 600 μl of DMEM medium containing 10% FBS was added to the lower chamber. After 36 h incubation at 37 °C, the matrigel in the upper chamber was gently removed using a cotton swab. The invaded cells were fixed with paraformaldehyde (4%) and stained with DAPI. The cells were photographed using fluorescence microscopy and counted from 5 random fields of microscope.
CCK-8 assay
200 μl of cell suspension (5 × 103 cells) were added into 96-well plates and incubated at 37 °C. At the appointed time, each well was added with 10 μl CCK-8 reagent (Dojindo Laboratories, Japan) and the absorbance at 450 nm was determined by a microplate spectrophotometer (Bio Tek, USA).
TOPFlash reporter assay
HCC-Ctrl or HCC-CYP2E1 cells were seeded in 24-well plates and incubated for 24 h at 37 °C. Then the cells were transfected with TOPFlash plasmid (800 ng/well) and pRL-TK plasmid (50 ng/well) using VigoFect reagent (Vigorous Biotechnology). The Dual Luciferase Reporter Assay Kit (Promega, Madison, WI, USA) was employed to to measure Luciferase and Renilla activities 48 h after transfection. The luciferase activity of each sample was normalized with the respective Renilla activity.
Detection of reactive oxygen species (ROS)
Cells grown to the appropriate 70–80% confluence in 6-well plates were stained with 20 μmol/l dihydroethidium (DHE, ABP Biosciences, Germany) for 1 h in the dark to assess the ROS level. ROS generation was indicated by red fluorescence and detected at Em: 485 nm and Ex: 610 nm with a fluorescence microscope.
Co-immunoprecipitation (co-IP) experiment
Protein extraction and quantification are as described for western blotting. Briefly, total protein (800 μg) was precleared with Protein A/G agarose (sc2003; Santa Cruz) at 4 ℃ for 30 min to remove non-specific protein. After centrifugation, the precleared supernatant was incubated with 2 μg of primary antibodies at 4 ℃ overnight and then 40 μl Protein A/G agarose was added and incubated at 4 ℃ for 4 h. Next, the agarose beads were collected by centrifugation at 3000 rpm and extensively washed with RIPA lysis buffer. Finally, the bound proteins were mixed with loading buffer and subjected to western blotting analysis. Mouse IgG was used as a negative control.
Immunohistochemistry
Liver tissues were embedded with paraffin, sectioned, dewaxed, and dehydrated with gradient ethanol. After antigen repair, the slides were incubated with CYP2E1 antibody (ab28146, Abcam; 1:125 dilution) at 4 °C overnight. Then, the slides were washed with TBST and incubated with HRP-conjugated secondary antibody polymer (SA00001-2, Proteintech, Wuhan, China; 1:250 dilution) followed by the addition of DAB solution and counterstained with hematoxylin.
Immunofluorescence cell staining
The cells seeded on the coverslips in the 24-well plates were cultured for 24 h. After fixing with 4% paraformaldehyde and permeabilizing with 0.5% Triton X-100, the cells were incubated with mouse anti-E-cadherin (2:250 dilution, AF0138, Beyotime) and rabbit anti-vimentin (2:250 dilution, 10366-1-AP, proteintech) at 4 ℃ overnight and then with fluorescence secondary antibodies (CoraLite 594, SA00013-3, goat anti-mouse IgG, Proteintech, 1:500 dilution; CoraLite 594, SA00013-4, goat anti-rabbit IgG, Proteintech, 1:500 dilution) for 30 min at 37 ℃. DAPI was used to stain the nuclei for 5 min and coverslips were mounted. Then, the cells were observed by the fluorescence microscope (OLYMpusBX43).
Tumor xenografts model
Four-week-old male BALB/c nude mice were provided by the Beijing Vital River Laboratory Animal Technology Company. After habituation for 3 days, 100 μl of MHCC-97H-GFP or MHCC-97H-CYP2E1 cell suspension (1 × 107 cells/ml) were injected subcutaneously into the right flanks of mice. Tumor volumes was recorded every 3 days. Tumor volume was calculated with the formula of [0.5 × length × width2]. At 35 days after injection, the nude mice were euthanized and tumors were collected for the subsequent orthotopic liver tumor model. These animal experiments were approved by the Animal Ethics Committee of Zhengzhou University and carried out in accordance with the guidelines of animal ethics.
Mouse liver orthotopic transplantation model
The tumors taken from the above xenograft nude mice were immediately minced into small pieces (about 1.5 mm × 1.5 mm × 1.5 mm). The left lobe of the liver of the 4.5-week-old male mice was extruded under anesthetization and a tunnel was made by a 10 ml syringe needle. Then 2 pieces of the tumors were deposited into the left lobe through the tunnel. Subsequently, the left lobe of the liver was returned to the abdominal cavity, and the muscle and skin were sutured. Ten weeks after the operation, the livers were removed and orthotopic tumors were counted.
200 μl of MHCC-97H-GFP or MHCC-97H-CYP2E1 cell suspension (1 × 106 cells/ml) were injected into the tail vein of 4.5-week-old mice. At the 9th week the nude mice were euthanized and the lungs removed. The lungs were fixed with 4% paraformaldehyde, embedded in paraffin, and cut into slices. The slices were moved onto glass slides, dewaxed, rehydrated in ethanol solution and followed by the addition of hematoxylin and eosin to determine the metastasis of cancer cells.
Statistical analyses
SPSS version 21.0 and GraphPad Prism 5.0 were used to perform statistical analysis and generate graphs, respectively. The Kolmogorov–Smirnov and Shapiro–Wilk methods were used to assess the normality of the data. For normal distribution data, a two-tailed Student’s t-test was used for pairwise comparisons. The Mann–Whitney U test was used to compare two groups with non-normal distribution data. The overall survival data were analyzed by Kaplan–Meier plots and the cut-off value for defining the subgroups was the median expression level of CYP2E1 mRNA. The sample was then divided into two groups. One group consisted of samples with CYP2E1 expression levels higher than the median, and the other group consisted of the remaining samples. A P value (two-tailed) < 0.05 indicated statistically significant.
Discussion
Our knowledge of the role of CYP2E1 in hepatocarcinogenesis is based on epidemiological and animal studies, with a primary focus on the role of CYP2E1 in the metabolic activation of procarcinogens; few studies have directly assessed the effects of CYP2E1 on HCC malignant phenotypes. Ho et al. [
14] reported that of CYP2E1 expression was significantly downregulated in HCC tissues and might serve as an independent prognostic factor for disease-free survival. Similar findings were reported in some earlier studies [
11,
12]. In addition, several reports have proposed that CYP2E1 overexpression is cytotoxic to the tumor cells and inhibits rapid cell proliferation upon ethanol treatment [
31,
32]. Here, our results show that the expression of CYP2E1 is decreased in HCC tissues, and low expression of CYP2E1 is associated with larger tumor diameter, vascular invasion, tumor differentiation, and short survival time in patients with HCC. Ectopic expression of CYP2E1 inhibited the proliferation, invasion and migration of HCC cells both in vivo and in vitro. Therefore, a decreased level of CYP2E1 might place the HCC cells at an advantage and favor HCC progression. These results support the hypothesis that CYP2E1 plays a protective role in the malignant biological behavior of HCC.
Wnt/β-catenin signaling is an evolutionarily highly conserved pathway and plays decisive roles in development and tissue homeostasis. Aberrant activation of the Wnt/β-catenin signaling cascade is one of the most frequent molecular events in HCC [
33] and conduces to the initiation, progression, invasion, and metastasis of HCC [
25]. When the Wnt ligand binds to its receptor, disheveled (Dvl) is recruited to the ligand-receptor complex, which provides a platform for Axin and GSK3β to bind, resulting in the dissociation of the cytoplasmic destruction complex, preventing β-catenin degradation. β-Catenin then forms a complex with TCF4/LEF1 in the nucleus, leading to the activation of Wnt/β-catenin target genes, such as
c-Myc,
Axin2,
LEF1. Dvl is therefore the central component of Wnt/β-catenin signaling and relays signals from Wnt receptors to β-catenin by rescuing β‐catenin from degradation [
10,
29]. Three homologous Dishevelled genes (
Dvl1,
Dvl2 and
Dvl3), which exhibit a high degree of similarity, have been found in humans [
34]. Increasing evidence indicates that Dvl plays critical roles in the progression of breast cancers, non-small cell lung cancer and astrocytomas [
34‐
36]. A recent study revealed that Dvl2 was overexpressed in HCC tissues and interacted with P62 to promote the invasion and migration of HCC cells [
37].
In the present study, CYP2E1 overexpression significantly inhibited Wnt/β-catenin signaling activity in HCC cells and Dvl2 expression level was reduced in CYP2E1-overexpressing HCC cells. Restoration of Dvl2 expression rescued the malignant phenotype of HCC cells. Previous studies have verified that Dvl2 is mainly regulated at the protein level by the ubiquitin–proteasome pathway. We thus speculated that the CYP2E1-blocked Wnt/β-catenin signaling pathway might depend on Dvl2 stability. KLHL12–Cullin-3 ubiquitin ligase was reported to mediate ubiquitination and degradation of Dvl2 under different physiological conditions [
30,
38]. Our results demonstrate that overexpression of CYP2E1 promotes the ubiquitination of Dvl2 in HCC cells. Further mechanistic research found that CYP2E1 strengthened the interaction of Dvl2‐KLHL12, thus inducing the ubiquitination and degradation of Dvl2 in CYP2E1-stable cells. Therefore, the present study establishes a link between CYP2E1 and Wnt/β-catenin signaling, and indicates that overexpression of CYP2E1 inhibits Wnt/β-catenin signaling by inducing the destabilization and promoting the degradation of Dvl2.
How does CYP2E1 regulate Wnt/β-Catenin signaling? CYP2E1 is one of the most active ROS-generating CYP isoforms and can produce high levels of ROS [
39]. ROS are increasingly being recognized as important signaling molecules involved in the regulation of many signaling pathways [
40]. Several studies have revealed the ability of ROS to regulate Wnt/β-catenin signaling [
41]. For example, H
2O
2 negatively regulates the Wnt pathway by downregulating β-catenin [
42]. Combretastatin A-1 phosphate, a microtubule polymerization inhibitor, has outstanding anti-cancer activity against HCC by inducing ROS accumulation and thereby inhibiting the Wnt/β-catenin pathway in HepG2 cells [
43].
A recent finding revealed that oxidative stress suppressed distant metastasis by melanoma cells in vivo [
44]. Large-scale multicentre clinical trials also showed that antioxidant supplementation not only failed to bring benefit to patients, but was related with a significant increase in cancer incidence [
45,
46]. In the current study, ROS level were significantly elevated in CYP2E1-overexpressing HCC cells comparing with the control cells. Treatment with CYP2E1 inhibitor or antioxidant not only restored the expression of proteins associated with the Wnt signaling pathway but also rescued the inhibitory phenotypes in CYP2E1 stable HCC cells. Therefore, we speculate that the inhibitory effect of CYP2E1 on the Wnt/β-catenin pathway is ROS-dependent and downregulation of CYP2E1 is beneficial to HCC cells to cope with the ROS stress and favor cancer growth.
Collectively, our studies provide novel insight into the role of CYP2E1 in HCC, independent of its activation of procarcinogens and mutagens. Ectopic expression of CYP2E1 inhibits cell proliferation, migration, invasion and EMT of HCC cells in vitro and inhibited tumor formation and lung metastasis in nude mice. The protective effect of CYP2E1 is attributed to its ability to manipulate Wnt/Dvl2/β-catenin signaling through ROS accumulation, which provides a potential target for the prevention and treatment of HCC.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.